MedMira Presents World's First OTC Rapid HIV Test to International Conference

MedMira Presents World's First OTC Rapid HIV Test to
International Conference
MiraCare(TM) Rapid HIV Test Shows 100% Agreement in Independent Evaluation



HALIFAX, March 2  /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow-through
diagnostic technology, announced today that it had presented its MiraCare(TM)
rapid, over-the-counter (OTC) test to participants of an international HIV
diagnostics conference hosted by the United States Centers for Disease Control
(CDC). The conference, entitled "HIV Diagnostics: New Developments and
Challenges", was attended by HIV-diagnostic healthcare personnel from the
private and public health sectors situated around the world.

The conference focused on reevaluating the options for HIV diagnosis and
confirmation with the availability of new HIV testing technologies, such as
rapid HIV tests. During the conference, MedMira presented the results of an
independent clinical evaluation of the MiraCare(TM) Rapid HIV Test which showed
100% agreement with traditional HIV testing methods. This performance
evaluation was carried out using all types of blood analytes: serum, plasma, as
well as venipuncture and fingerstick whole blood.

"Our MiraCare(TM) Rapid HIV Test is one of the newest and greatest developments
in today's global HIV diagnostic market. This conference provided an ideal
forum to introduce our new OTC HIV test to the key individuals in the
international healthcare community," said Hermes Chan, President and Chief
Operating Officer of MedMira.

Chan continued, "The MiraCare(TM) test offers a viable alternative to people
who would otherwise not choose to be tested for HIV. Although the stigma
associated with HIV testing has decreased substantially in recent years, many
people still prefer the option of performing an HIV test in the privacy of
their home. This has been proven by the marketing success of the MiraCare(TM)
test in Hong Kong and Macao."

The MiraCare(TM) Rapid HIV Test utilizes MedMira's world's fastest flow-
through technology platform, at only 3-minutes. The speed and accuracy of the
test, as demonstrated by the results of this most recent independent
evaluation, reflect the value of this product to all levels of consumers (from
physicians and clinicians to pharmacists and the general public) in comparison
to traditional testing methods, which take days or weeks to provide test
results.

The MiraCare(TM) Rapid HIV Test is sold as a complete test package containing
all required components and instructions for an individual to conduct the test
quickly using a drop of fingerstick whole blood, with results in just 3
minutes. The MiraCare(TM) Rapid HIV Test is also available in a
serum/plasma/venipuncture whole blood format for use by healthcare
professionals.

About MedMira

MedMira is the leading global manufacturer and marketer of in vitro flow-
though rapid diagnostic tests for the clinical laboratory market. MedMira's
tests provide reliable, rapid diagnosis in just 3 minutes for the detection of
human antibodies in human serum, plasma or whole blood for diseases such as
HIV. The United States FDA and the SFDA in the People's Republic of China have
approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests,
respectively. For more information visit MedMira's website at
http://www.medmira.com/.

MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in
clinical laboratories and hospitals where professional counseling and patient
treatment are immediately available.

MedMira markets its rapid tests worldwide in such countries as the United
States, Canada, South Africa and China. Its corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada with a representative
office in Beijing, China.

This news release contains forward-looking statements, which involve risk and
uncertainties and reflect the company's current expectation regarding future
events. Actual events could materially differ from those projected herein and
depend on a number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the company quarterly
filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this statement. 

DATASOURCE: MedMira Inc.



CONTACT: Media Contact: Investor Relations, Dr. James Smith:

[phone] or e-mail: 

Copyright